Aggressiveness of SJL/J lymphomas correlates with absence of H-2Ds antigens.
Aggressiveness of SJL/J lymphomas correlates with absence of H-2Ds antigens.
复制标题
SJL/J 淋巴瘤的侵袭性与 H-2D 抗原的缺失相关。
DOI：
10.4049/jimmunol.132.2.945
复制
发表时间：
1984
影响因子：
4.4
通讯作者：
S. Lerman
中科院分区：
文献类型：
--
作者：
E. Rosloniec;M. Kuhn;C. Genyea;A. Reed;J. Jennings;A. A. Giraldo;K. Beisel;S. Lerman
SJL/J淋巴瘤在移植各自的H-2Ds阳性自发性肿瘤后出现H-2Ds阴性变体。在检查的9例自发性SJL/J淋巴瘤中，只有2例含有可检测数量的H-2Ds阴性肿瘤细胞。然而，在7例成功移植的肿瘤中，4例在第二次移植时主要为H-2Ds阴性肿瘤。还发现长期SJL/J淋巴瘤系RCS 5和SJL/SJL为H-2Ds阴性。H-2Ks和I-As的表达在所检查的所有肿瘤细胞系上维持。H-2Ds阴性的肿瘤细胞是一致的同源淋巴细胞增殖的刺激因子，而维持H-2Ds表达的肿瘤在其刺激能力上各不相同。在同基因小鼠中达到发病率所需的移植时间与H-2Ds的肿瘤细胞表达相关。维持H-2Ds表达的肿瘤的侵袭性较低，需要57至150天才能产生发病率，而高度侵袭性的H-2Ds阴性肿瘤在四分之一的细胞剂量（10（7）个细胞）下仅需要7至10天。基于脾脏重量（经体重校正）的生长曲线分析表明，根据H-2Ds表达和刺激同系淋巴细胞增殖的能力，可以鉴定出三种类型的SJL/J淋巴瘤：1）惰性、非刺激性H-2Ds阳性肿瘤; 2）惰性、刺激性H-2Ds阳性肿瘤; 3）高度侵袭性、刺激性H-2Ds阴性肿瘤。
SJL/J lymphomas emerged as H-2Ds-negative variants upon transplantation of their respective H-2Ds-positive spontaneous tumors. Of nine spontaneous SJL/J lymphomas examined, only two contained detectable numbers of H-2Ds-negative tumor cells. Of seven successfully transplanted tumors, however, four emerged as predominantly H-2Ds-negative tumors by their second transplantation. Long term SJL/J lymphoma lines, RCS 5 and SJL/SJL, were also found to be H-2Ds-negative. The expression of H-2Ks and I-As were maintained on all tumor lines examined. H-2Ds-negative tumor cells were consistent stimulators of syngeneic lymphoproliferation, whereas tumors maintaining H-2Ds expression varied in their stimulatory capacity. Transplantation times required to achieve morbidity in syngeneic mice correlated with tumor cell expression of H-2Ds. Tumors maintaining H-2Ds expression were less aggressive and required 57 to 150 days to produce morbidity compared with highly aggressive H-2Ds-negative tumors that required only 7 to 10 days at one-quarter of the cell dose (10(7) cells). Growth curve analysis based on spleen weights (corrected for body weight) indicated that three types of SJL/J lymphomas could be identified based on their expression of H-2Ds and ability to stimulate syngeneic lymphoproliferation: 1) indolent, nonstimulatory H-2Ds-positive tumors; 2) indolent, stimulatory H-2Ds-positive tumors; and 3) highly aggressive, stimulatory H-2Ds-negative tumors.